Last updated: March 2, 2026
What is NDC 67386-0314?
NDC 67386-0314 refers to Aflibercept Injection (Eylea), a vascular endothelial growth factor (VEGF) inhibitor used primarily for treating neovascular age-related macular degeneration (AMD), diabetic macular edema, and other retinal diseases. The product is marketed by Bayer, with formulations typically administered via intravitreal injections.
Market Overview
Market Size and Growth
The global ophthalmology drug market, driven by increasing prevalence of AMD, diabetic retinopathy, and other retinal diseases, is projected to reach USD 10 billion by 2025, growing at an annual rate of approximately 4.5%. The market for VEGF inhibitors like aflibercept constitutes a significant portion of this revenue.
Key Drivers:
- Rising aging populations worldwide
- Increased diagnosis rates of retinal diseases
- Advances in intravitreal injection techniques
- High spending on ophthalmic treatments
Competitive Landscape
Major competitors include:
- Ranibizumab (Lucentis) by Novartis
- Bevacizumab (Avastin) by Genentech (off-label use in ophthalmology)
- Faricimab (AbbVie's dual VEGF and Ang-2 inhibitor) expected to enter the market soon
Market Share Insights
Aflibercept’s market share in ophthalmic VEGF inhibitors is approximately 50-55% in the U.S., with some regional variations. It commands a premium pricing strategy relative to off-label bevacizumab, which remains popular due to lower cost.
Distribution Channels
- Specialty ophthalmology clinics
- Hospital outpatient departments
- Optometry practices with infusion capacity
Price Analysis
Current Pricing (United States)
The wholesale acquisition cost (WAC) per injection for aflibercept (Eylea) is approximately USD 2,000–2,200. Variations depend on formulation, dosage, and patient insurance coverage.
| Attribute |
Details |
| Price per injection |
USD 2,000–2,200 |
| Typical annual treatment |
7–12 injections (monthly or bimonthly) |
| Annual treatment cost |
USD 14,000–26,400 |
Reimbursement and Cash Price
Insurance reimbursements typically cover about 85–100% of the treatment cost, with out-of-pocket costs for patients ranging USD 50–300 per injection, depending on insurance plans.
Pricing Trends and Projections (Next 5 Years)
| Year |
Estimated Price per Injection |
Factors Influencing Price Changes |
| 2023 |
USD 2,100 |
Stable, with minor inflation adjustments |
| 2024 |
USD 2,100–2,200 |
Possible reductions if biosimilars or competitors gain market share |
| 2025 |
USD 2,050–2,150 |
Price stabilization amid biosimilar development and market saturation |
| 2026 |
USD 2,000–2,100 |
Slight decline if biosimilar uptake increases or new therapies gain approval |
| 2027 |
USD 1,950–2,050 |
Potential price pressure from generics and alternative treatments |
Impact of Biosimilars
Biosimilar versions of aflibercept are in early development stages, with market entry expected around 2024–2026. These could limit pricing power and catalyze price declines by 10–15%.
Regulatory and Policy Impact
- U.S. FDA approved aflibercept in 2011.
- Pricing regulations or indications for price caps could influence costs.
- Patent expiry expected around 2024–2026, opening market for biosimilars.
Future Market Dynamics
- Expansion into new indications (e.g., diabetic retinopathy, myopic choroidal neovascularization)
- Development of longer-acting formulations to reduce injection frequency
- Adoption of biosimilars potentially reducing prices by 20–30%
- Competitive approval of new drugs like Faricimab may alter market shares
Key Takeaways
- The current USD 2,000–2,200 cost per injection remains the dominant pricing structure.
- Market growth driven by demographic trends and increased diagnosis.
- Biosimilars threaten to reduce prices by up to 30% over the next three years.
- Penetration of new therapies and formulations may influence future pricing strategies.
- Competition from newer agents like Faricimab could shift market dynamics by 2025.
FAQs
1. When are biosimilars expected to hit the market for aflibercept (NDC 67386-0314)?
Biosimilars are projected to enter the market around 2024–2026, following patent expiry and regulatory approval.
2. How does the cost of aflibercept compare to alternatives?
Off-label bevacizumab costs approximately USD 50–200 per injection, while ranibizumab varies around USD 1,700–2,000, making aflibercept comparable but with a different dosing schedule.
3. What factors could influence future price reductions?
Introduction of biosimilars, competition from new therapies, and regulatory price controls are primary drivers.
4. Are there regional differences in pricing?
Yes, prices are generally higher in the U.S. and Europe due to healthcare system structures, reimbursement policies, and negotiated discounts.
5. What role does new drug development play in market pricing?
Innovations like longer-acting formulations or combination therapies could alter overall treatment costs and market shares.
Sources:
[1] MarketWatch. (2023). Ophthalmic drugs market size and forecast.
[2] IQVIA. (2022). US ophthalmology drug pricing and reimbursement data.
[3] FDA. (2011). Approval notice for aflibercept.
[4] FiercePharma. (2023). Biosimilars in ophthalmology: developments and market prospects.
[5] EvaluatePharma. (2022). 5-year outlook for ophthalmic biologics.
